View in EDS HTML Full Text PDF Full Text

Outcomes in New User Cohorts of SGLT2 Inhibitors or GLP-1 Receptor Agonists with Type 2 Diabetes and Chronic Kidney Disease.

Saved in:
Bibliographic Details
Title: Outcomes in New User Cohorts of SGLT2 Inhibitors or GLP-1 Receptor Agonists with Type 2 Diabetes and Chronic Kidney Disease.
Authors: Layton JB; RTI Health Solutions, Research Triangle Park, NC, USA., Ziemiecki R; RTI Health Solutions, Research Triangle Park, NC, USA., Johannes CB; RTI Health Solutions, Waltham, MA, USA., Pladevall-Vila M; RTI Health Solutions, Barcelona, Spain.; The Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit, MI, USA., Khan AM; RTI Health Solutions, Waltham, MA, USA., Ebert N; Institute of Public Health, Charité-Universitätsmedizin, Berlin, Germany., Kovesdy CP; Division of Nephrology, Department of Medicine, University of Tennessee Health Science Center, Memphis, TN, USA., Christiansen CF; Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark., García-Sempere A; Health Services Research and Pharmacoepidemiology Unit, Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO), Valencia, Spain., Kanegae H; Genki Plaza Medical Centre for Health Care, Tokyo, Japan., Coleman CI; University of Connecticut School of Pharmacy, Storrs, CT, USA.; Evidence-Based Practice Center, Hartford Hospital, Hartford, CT, USA., Walsh M; Division of Nephrology, Department of Medicine, McMaster University, Hamilton, ON, Canada., Andersen IT; Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark., Rodríguez-Bernal C; Health Services Research and Pharmacoepidemiology Unit, Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO), Valencia, Spain., Cabaniñas CR; Health Services Research and Pharmacoepidemiology Unit, Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO), Valencia, Spain., Thomsen RW; Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark., Farjat AE; Bayer AG, Müllerstrasse 178, 13353, Berlin, Germany., Gay A; Bayer AG, Müllerstrasse 178, 13353, Berlin, Germany., Gee P; National Kidney Foundation Advocacy, Richmond, VA, USA., Hurtado I; Health Services Research and Pharmacoepidemiology Unit, Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO), Valencia, Spain., Kashihara N; Kawasaki Geriatric Medical Center, Okayama, Japan., Munch PV; Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark., Liu F; Bayer AG, Müllerstrasse 178, 13353, Berlin, Germany., Okami S; Bayer AG, Müllerstrasse 178, 13353, Berlin, Germany., Yamashita S; Bayer AG, Müllerstrasse 178, 13353, Berlin, Germany., Yano Y; Department of General Medicine, Faculty of Medicine, Juntendo University, Tokyo, Japan., Vizcaya D; Bayer AG, Müllerstrasse 178, 13353, Berlin, Germany., Oberprieler NG; Bayer AG, Müllerstrasse 178, 13353, Berlin, Germany. niki.oberprieler@bayer.com.
Source: Diabetes therapy : research, treatment and education of diabetes and related disorders [Diabetes Ther] 2025 Aug; Vol. 16 (8), pp. 1597-1614. Date of Electronic Publication: 2025 Jun 04.
Publication Type: Journal Article
Journal Info: Publisher: Springer Healthcare Country of Publication: United States NLM ID: 101539025 Publication Model: Print-Electronic Cited Medium: Print ISSN: 1869-6953 (Print) Linking ISSN: 18696961 NLM ISO Abbreviation: Diabetes Ther Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40465145
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Outcomes in New User Cohorts of SGLT2 Inhibitors or GLP-1 Receptor Agonists with Type 2 Diabetes and Chronic Kidney Disease.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Layton+JB%22">Layton JB</searchLink>; RTI Health Solutions, Research Triangle Park, NC, USA.<br /><searchLink fieldCode="AU" term="%22Ziemiecki+R%22">Ziemiecki R</searchLink>; RTI Health Solutions, Research Triangle Park, NC, USA.<br /><searchLink fieldCode="AU" term="%22Johannes+CB%22">Johannes CB</searchLink>; RTI Health Solutions, Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22Pladevall-Vila+M%22">Pladevall-Vila M</searchLink>; RTI Health Solutions, Barcelona, Spain.; The Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit, MI, USA.<br /><searchLink fieldCode="AU" term="%22Khan+AM%22">Khan AM</searchLink>; RTI Health Solutions, Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22Ebert+N%22">Ebert N</searchLink>; Institute of Public Health, Charité-Universitätsmedizin, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Kovesdy+CP%22">Kovesdy CP</searchLink>; Division of Nephrology, Department of Medicine, University of Tennessee Health Science Center, Memphis, TN, USA.<br /><searchLink fieldCode="AU" term="%22Christiansen+CF%22">Christiansen CF</searchLink>; Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark.<br /><searchLink fieldCode="AU" term="%22García-Sempere+A%22">García-Sempere A</searchLink>; Health Services Research and Pharmacoepidemiology Unit, Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO), Valencia, Spain.<br /><searchLink fieldCode="AU" term="%22Kanegae+H%22">Kanegae H</searchLink>; Genki Plaza Medical Centre for Health Care, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Coleman+CI%22">Coleman CI</searchLink>; University of Connecticut School of Pharmacy, Storrs, CT, USA.; Evidence-Based Practice Center, Hartford Hospital, Hartford, CT, USA.<br /><searchLink fieldCode="AU" term="%22Walsh+M%22">Walsh M</searchLink>; Division of Nephrology, Department of Medicine, McMaster University, Hamilton, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Andersen+IT%22">Andersen IT</searchLink>; Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark.<br /><searchLink fieldCode="AU" term="%22Rodríguez-Bernal+C%22">Rodríguez-Bernal C</searchLink>; Health Services Research and Pharmacoepidemiology Unit, Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO), Valencia, Spain.<br /><searchLink fieldCode="AU" term="%22Cabaniñas+CR%22">Cabaniñas CR</searchLink>; Health Services Research and Pharmacoepidemiology Unit, Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO), Valencia, Spain.<br /><searchLink fieldCode="AU" term="%22Thomsen+RW%22">Thomsen RW</searchLink>; Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark.<br /><searchLink fieldCode="AU" term="%22Farjat+AE%22">Farjat AE</searchLink>; Bayer AG, Müllerstrasse 178, 13353, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Gay+A%22">Gay A</searchLink>; Bayer AG, Müllerstrasse 178, 13353, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Gee+P%22">Gee P</searchLink>; National Kidney Foundation Advocacy, Richmond, VA, USA.<br /><searchLink fieldCode="AU" term="%22Hurtado+I%22">Hurtado I</searchLink>; Health Services Research and Pharmacoepidemiology Unit, Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO), Valencia, Spain.<br /><searchLink fieldCode="AU" term="%22Kashihara+N%22">Kashihara N</searchLink>; Kawasaki Geriatric Medical Center, Okayama, Japan.<br /><searchLink fieldCode="AU" term="%22Munch+PV%22">Munch PV</searchLink>; Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark.<br /><searchLink fieldCode="AU" term="%22Liu+F%22">Liu F</searchLink>; Bayer AG, Müllerstrasse 178, 13353, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Okami+S%22">Okami S</searchLink>; Bayer AG, Müllerstrasse 178, 13353, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Yamashita+S%22">Yamashita S</searchLink>; Bayer AG, Müllerstrasse 178, 13353, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Yano+Y%22">Yano Y</searchLink>; Department of General Medicine, Faculty of Medicine, Juntendo University, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Vizcaya+D%22">Vizcaya D</searchLink>; Bayer AG, Müllerstrasse 178, 13353, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Oberprieler+NG%22">Oberprieler NG</searchLink>; Bayer AG, Müllerstrasse 178, 13353, Berlin, Germany. niki.oberprieler@bayer.com.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101539025%22">Diabetes therapy : research, treatment and education of diabetes and related disorders</searchLink> [Diabetes Ther] 2025 Aug; Vol. 16 (8), pp. 1597-1614. <i>Date of Electronic Publication: </i>2025 Jun 04.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer+Healthcare%22">Springer Healthcare </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101539025 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Print <i>ISSN: </i>1869-6953 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2218696961%22">18696961 </searchLink><i>NLM ISO Abbreviation: </i>Diabetes Ther <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40465145
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s13300-025-01750-7
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1597
    Titles:
      – TitleFull: Outcomes in New User Cohorts of SGLT2 Inhibitors or GLP-1 Receptor Agonists with Type 2 Diabetes and Chronic Kidney Disease.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Layton JB
      – PersonEntity:
          Name:
            NameFull: Ziemiecki R
      – PersonEntity:
          Name:
            NameFull: Johannes CB
      – PersonEntity:
          Name:
            NameFull: Pladevall-Vila M
      – PersonEntity:
          Name:
            NameFull: Khan AM
      – PersonEntity:
          Name:
            NameFull: Ebert N
      – PersonEntity:
          Name:
            NameFull: Kovesdy CP
      – PersonEntity:
          Name:
            NameFull: Christiansen CF
      – PersonEntity:
          Name:
            NameFull: García-Sempere A
      – PersonEntity:
          Name:
            NameFull: Kanegae H
      – PersonEntity:
          Name:
            NameFull: Coleman CI
      – PersonEntity:
          Name:
            NameFull: Walsh M
      – PersonEntity:
          Name:
            NameFull: Andersen IT
      – PersonEntity:
          Name:
            NameFull: Rodríguez-Bernal C
      – PersonEntity:
          Name:
            NameFull: Cabaniñas CR
      – PersonEntity:
          Name:
            NameFull: Thomsen RW
      – PersonEntity:
          Name:
            NameFull: Farjat AE
      – PersonEntity:
          Name:
            NameFull: Gay A
      – PersonEntity:
          Name:
            NameFull: Gee P
      – PersonEntity:
          Name:
            NameFull: Hurtado I
      – PersonEntity:
          Name:
            NameFull: Kashihara N
      – PersonEntity:
          Name:
            NameFull: Munch PV
      – PersonEntity:
          Name:
            NameFull: Liu F
      – PersonEntity:
          Name:
            NameFull: Okami S
      – PersonEntity:
          Name:
            NameFull: Yamashita S
      – PersonEntity:
          Name:
            NameFull: Yano Y
      – PersonEntity:
          Name:
            NameFull: Vizcaya D
      – PersonEntity:
          Name:
            NameFull: Oberprieler NG
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 08
              Text: 2025 Aug
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-print
              Value: 1869-6953
          Numbering:
            – Type: volume
              Value: 16
            – Type: issue
              Value: 8
          Titles:
            – TitleFull: Diabetes therapy : research, treatment and education of diabetes and related disorders
              Type: main
ResultId 1